• measurement of the effects of laser hair removal on the immunohistochemical staining properties of human hair follicles, including the putative stem cells of the bulge region.
  

• Hair Removal
  

Laser hair removal has become one of the most popular and commonly performed procedures in cosmetic dermatology. However, relatively little is known about the mechanisms involved in achieving what clinically appears to be permanent reduction in hair density in treated areas. We postulate that in order to achieve permanent hair reduction, stem cells located in the bulge region of the follicle must be destroyed. Recently, a marker of follicular stem cells (keratin 15) has been identified and noted to be detectable using immunohistochemical techniques. In addition, several other immunohistochemical markers for various components of the hair follicle are available.

We propose to quantitatively measure the effects of laser hair removal on the immunohistochemical staining properties of treated follicles with respect to keratin 15 and other follicular markers. We hypothesize that the degree of such staining will be greatly reduced following laser therapy, thus providing, to our knowledge, the first biochemical evidence to support permanence of the treatment’s effects.

Inclusion Criteria:

1. Age 18 years or older of either gender.
2. At least moderately dense axillary (armpit) hair that is dark (not blonde or white) in color.
3. Subjects must understand and sign the informed consent documents prior to participation.
4. Subjects must be in generally good health.
5. Subjects must be willing and able to comply with the requirements of the protocol
6. You must live within a reasonable driving distance of Ann Arbor, Michigan, and/or be able to attend all of the scheduled appointments during the study.

Exclusion Criteria:

1. Oral retinoid use within one year of study entry.
2. History of prior laser therapy or electrolysis of the axillae.
3. Subjects who do not desire permanent reduction in axillary hair.
4. Non-compliant subjects.
5. Pregnant or nursing subjects.
6. Subjects with a significant medical history or concurrent illness/condition that the investigator(s) feel is not safe for study participation.
7. Active infection of the site to be treated or a history of herpes simplex or zoster infection at the site to be treated.
8. History of keloid scar formation.
9. Known history of allergy or sensitivity to lidocaine.
10. History of waxing, plucking, or bleaching of the hair for 6 weeks prior to the treatment.